150 related articles for article (PubMed ID: 25349561)
1. Parthenolide Sensitizes Human Colorectal Cancer Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand through Mitochondrial and Caspase Dependent Pathway.
Trang KT; Kim SL; Park SB; Seo SY; Choi CH; Park JK; Moon JC; Lee ST; Kim SW
Intest Res; 2014 Jan; 12(1):34-41. PubMed ID: 25349561
[TBL] [Abstract][Full Text] [Related]
2. Parthenolide enhances sensitivity of colorectal cancer cells to TRAIL by inducing death receptor 5 and promotes TRAIL-induced apoptosis.
Kim SL; Liu YC; Park YR; Seo SY; Kim SH; Kim IH; Lee SO; Lee ST; Kim DG; Kim SW
Int J Oncol; 2015 Mar; 46(3):1121-30. PubMed ID: 25502339
[TBL] [Abstract][Full Text] [Related]
3. 3-Bromopyruvate potentiates TRAIL-induced apoptosis in human colon cancer cells through a reactive oxygen species- and caspase-dependent mitochondrial pathway.
Abbaszadeh H; Valizadeh A; Mahdavinia M; Teimoori A; Pipelzadeh MH; Zeidooni L; Alboghobeish S
Can J Physiol Pharmacol; 2019 Dec; 97(12):1176-1184. PubMed ID: 31491344
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
[TBL] [Abstract][Full Text] [Related]
5. Effects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480.
Sun T; Zhu T; Liang X; Yang S; Zhao R
Med Sci Monit; 2018 Apr; 24():2550-2561. PubMed ID: 29695684
[TBL] [Abstract][Full Text] [Related]
6. Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis.
Hernandez A; Thomas R; Smith F; Sandberg J; Kim S; Chung DH; Evers BM
Surgery; 2001 Aug; 130(2):265-72. PubMed ID: 11490359
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer.
Kim SL; Kim SH; Trang KT; Kim IH; Lee SO; Lee ST; Kim DG; Kang SB; Kim SW
Cancer Lett; 2013 Jul; 335(2):479-86. PubMed ID: 23507557
[TBL] [Abstract][Full Text] [Related]
8. Acetylshikonin Sensitizes Hepatocellular Carcinoma Cells to Apoptosis through ROS-Mediated Caspase Activation.
Hong M; Li J; Li S; M Almutairi M
Cells; 2019 Nov; 8(11):. PubMed ID: 31752383
[TBL] [Abstract][Full Text] [Related]
9. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
10. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein.
Frese S; Brunner T; Gugger M; Uduehi A; Schmid RA
J Thorac Cardiovasc Surg; 2002 Jan; 123(1):168-74. PubMed ID: 11782771
[TBL] [Abstract][Full Text] [Related]
12. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase.
Nakshatri H; Rice SE; Bhat-Nakshatri P
Oncogene; 2004 Sep; 23(44):7330-44. PubMed ID: 15286701
[TBL] [Abstract][Full Text] [Related]
13. Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation.
Carlisi D; D'Anneo A; Angileri L; Lauricella M; Emanuele S; Santulli A; Vento R; Tesoriere G
J Cell Physiol; 2011 Jun; 226(6):1632-41. PubMed ID: 21413021
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
El Fajoui Z; Toscano F; Jacquemin G; Abello J; Scoazec JY; Micheau O; Saurin JC
Gastroenterology; 2011 Aug; 141(2):663-73. PubMed ID: 21683075
[TBL] [Abstract][Full Text] [Related]
15. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol sensitizes lung cancer cell to TRAIL by p53 independent and suppression of Akt/NF-κB signaling.
Rasheduzzaman M; Jeong JK; Park SY
Life Sci; 2018 Sep; 208():208-220. PubMed ID: 30031063
[TBL] [Abstract][Full Text] [Related]
17. Apigenin Sensitizes Huh-7 Human Hepatocellular Carcinoma Cells to TRAIL-induced Apoptosis.
Kim EY; Kim AK
Biomol Ther (Seoul); 2012 Jan; 20(1):62-7. PubMed ID: 24116276
[TBL] [Abstract][Full Text] [Related]
18. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo.
Shankar S; Chen X; Srivastava RK
Prostate; 2005 Feb; 62(2):165-86. PubMed ID: 15389801
[TBL] [Abstract][Full Text] [Related]
19. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells.
Ballestrero A; Nencioni A; Boy D; Rocco I; Garuti A; Mela GS; Van Parijs L; Brossart P; Wesselborg S; Patrone F
Clin Cancer Res; 2004 Feb; 10(4):1463-70. PubMed ID: 14977850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
